Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Terry Stone

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Featured in The Dallas Morning News

Executives who care about diversity should examine the track in their companies to senior management.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

New Predictions on COVID-19 Vaccines and Herd Immunity

How COVID-19 case counts and vaccines may get us back to normalcy by June.

Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

The nation's new "normal" may not come until Q4 of 2021. Companies must consider what is sustainable and where to adjust for the long haul.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

As parts of the nation begin to re-open, new considerations are unfolding that leaders struggle to manage.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Businesses must prepare now for the long haul of COVID-19 suppression if they are to survive in a changed economy.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman
Partner and Co-Lead of Digital Transformation, EMEA, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

41% of founders and co-founders at this year’s StartUp Health festival were female. Here’s why this matters for (both female and male) healthcare leaders.

Editor, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

The Illusions and Temptations of Successful M&A

What we can learn from industries beyond healthcare where M&A activities have generated greater returns.

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Men hold most (87 percent) of C-suite roles at healthcare’s top ranks. But why?

Partner, Health and Life Sciences, Oliver Wyman
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

What over 70 women leaders, from those moving up the ladder to those at its peak, said about their identity.

Director, Strategy & Corporate Development, Landmark Health
Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman

Oliver Wyman's research findings on diversity in healthcare leadership (some of which surprised us).

Managing Partner, Health and Life Sciences, and Global Chair for I&D, Oliver Wyman
Director, Strategy & Corporate Development, Landmark Health
Principal, Oliver Wyman
Consultant

Insights in your inbox

Subscribe